Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today.
Category: NYSE:PFE
The Challenges In Bringing An Anti-Aging Pill To Market
But an anti-aging pill available for the masses is not around the corner. It might not even appear in our lifetime.
Does The NIH Deserve A Piece Of Biopharma’s Profits?
Decades ago, the U.S. believed that investments in research were important for the public good – for our defense, for our health and for our economic prosperity.
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
What is driving these companies to develop drugs with poorer sales prospects than were previously deemed essential?
Big Pharma Should Accept Cap On Drug Price Increases
By capping price increases to inflation levels, PhRMA can show it cares about patients, drug costs and accessibility of its breakthroughs.
The Demise Of A Once Promising Pancreatic Cancer Drug Is All Too Common
Companies as small as Nivien or as large as Pfizer find the chemical tools and run the experiments that prove or disprove medical hypotheses.
Can The Record Breaking Number Of FDA New Drug Approvals Continue?
Despite these possibilities, the boom in new drugs is likely to continue benefiting the industry and more importantly, the patients anxiously waiting for these new treatments.
The Claim By Bristol-Myers Squibb CEO That The New Company Will Be A ‘Magnet For Talent’ Is Naïve
A “magnet for talent” – really? Would you want to join an organization that is in the midst of such turmoil?
Lessons From The Biggest Pharma Drug Launches Of All Time
But given the medical breakthroughs being made, it is likely that in the coming years there will be new entries in this list – and high priced ones at that.
Takeda Acquisition Of Shire May Bode Well For R&D Staff
“We think that the fit is very strong between Takeda and Shire. We foresee minimal disruption on the R&D front.”
